

AMENDMENT TO THE CLAIMS

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In the Claims:

1. (Currently amended) A planiplaniform planiform transmucosal pharmaceutical administration form for which is distinguished by low solubility within the oral cavity and release of active compound in the oral cavity which is rapid and constant over a relatively long period, characterized in that the administration form it is composed of a solid solution of the active compound

a) in a phosphatidylcholine fraction in which the fatty acid residues are at least 90% saturated and the administration form comprises at least 80% by weight of the phosphatidylcholine fraction, or

b) in a mixture of the phosphatidylcholine fraction specified under a) and a copolymer composed of maleic acid and an alkyl vinyl ether, and,

where appropriate, further pharmaceutically tolerated adjuvants and additives

wherein the active compound is selected from the group consisting of epibatidine, mecamylamine, hypericin, CP-52655, bupropion, oxazolidinone compounds, befloxatones, cannabinoid receptor (CB 1) antagonist SR 141716 and salts thereof.

2. (Cancelled)

3. (Original) The administration form as claimed in claim 1, characterized in that it comprises polyvinylpyrrolidone as additive.

4. (Original) The administration form as claimed in claim 1, characterized in that the active compound is suitable for treating the abuse of addiction-inducing drugs and dependence on these drugs.

5. (Cancelled)

6. (Cancelled)

7. (Currently amended) The administration form as claimed in claim 1, characterized in that the active compound is epibatidine and/or a derivative salt of this compound.

8. (Cancelled)

9. (Currently amended) The administration form as claimed in claim 1, characterized in that the active compound is selected from the compound group mecamylamine, hypericin, CP-52655 and bupropion bupropion and/or a salt thereof one of their derivatives.

10. (Currently amended) The administration form as claimed in claim 1, characterized in that the active compound is selected from the group of oxazolidinone compounds derivatives and befloxatones.

11. (Original) The administration form as claimed in claim 1, characterized in that the active compound is the cannabinoid receptor (CB 1) antagonist SR 141716.

12. (New) The administration form as claimed in claim 1, characterized in that the administration form is composed of a solid solution of the active compound in a phosphatidylcholine fraction in which the fatty acid residues are at least 90% saturated and the administration form comprises at least 80% by weight of the phosphatidylcholine fraction.

13. (New) The administration form as claimed in claim 1, characterized in that the administration form is composed of a solid solution of the active compound in a mixture of a phosphatidylcholine fraction in which the fatty acid residues are at least 90% saturated and the administration form comprises at least 80% by weight of the phosphatidylcholine fraction and a copolymer composed of maleic acid and an alkyl vinyl ether.